{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:16:41Z","timestamp":1792919801118,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.trre.2025.100960","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T15:55:33Z","timestamp":1755878133000},"page":"100960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of disease-modifying drugs in patients with transthyretin amyloidosis after liver transplantation: a systematic review"],"prefix":"10.1016","volume":"39","author":[{"given":"Christiane","family":"Santo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristhian","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vaz Kerges Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Dabarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2025.100960_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2025.103019","article-title":"Hereditary transthyretin amyloidosis (ATTRv)","volume":"50","author":"Triposkiadis","year":"2025","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.trre.2025.100960_bb0010","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231191590","article-title":"A narrative review and expert recommendations on the assessment of the clinical manifestations, follow-up, and management of post-OLT patients with ATTRv amyloidosis","volume":"16","author":"Casasnovas","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.trre.2025.100960_bb0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-6143.2006.01585.x","article-title":"Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients","volume":"7","author":"Yazaki","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100960_bb0020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00007890-199707150-00014","article-title":"Progression of ventricular wall thickening after liver transplantation for familial amyloidosis","volume":"64","author":"Dubrey","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100960_bb0025","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1212\/WNL.0b013e318248df18","article-title":"Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy","volume":"78","author":"Yamashita","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.trre.2025.100960_bb0030","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100960_bb0035","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/brain\/123.7.1495","article-title":"The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation","volume":"123","author":"Adams","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.trre.2025.100960_bb0040","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000006543","article-title":"Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy","volume":"91","author":"Coelho","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.trre.2025.100960_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"HELIOS-A collaborators. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.trre.2025.100960_bb0050","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.trre.2025.100960_bb0055","article-title":"Antibody ALXN2220 (formerly NI006) for the treatment of transthyretin cardiac amyloidosis","author":"Pillai","year":"2025","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.trre.2025.100960_bb0060","article-title":"CRISPR\/Cas9 gene editing: a new hope for transthyretin amyloidosis treatment","volume":"83","author":"Shahzad","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.trre.2025.100960_bb0065","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/ajt.17009","article-title":"Patisiran post-LT study group. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation","volume":"22","author":"Schmidt","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100960_bb0070","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/13506129.2020.1784134","article-title":"TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients","volume":"27","author":"Moshe-Lilie","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.trre.2025.100960_bb0075","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1007\/s00415-022-10978-3","article-title":"Clinical improvement after change of therapy from tafamidis to patisiran in progressive TTR amyloidosis post-liver transplantation","volume":"269","author":"Bulinski","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.trre.2025.100960_bb0080","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3988\/jcn.2017.13.4.444","article-title":"Tafamidis for a transplant patient with transthyretin amyloid polyneuropathy","volume":"13","author":"Romero-Imbroda","year":"2017","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.trre.2025.100960_bb0085","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2021.1904391","article-title":"Development of late amyloid cardiomyopathy following liver transplantation for hereditary Val30Met transthyretin amyloidosis","volume":"28","author":"Gondi","year":"2021","journal-title":"Amyloid"},{"key":"10.1016\/j.trre.2025.100960_bb0090","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/13506129.2015.1031373","article-title":"Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report","volume":"22","author":"Kon","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.trre.2025.100960_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2024.103083","article-title":"Preliminary efficacy and safety analysis of Tafamidis in post-liver transplant patients with hereditary transthyretin cardiac amyloidosis","volume":"56","author":"Okumura","year":"2025","journal-title":"Arch Med Res"},{"key":"10.1016\/j.trre.2025.100960_bb0100","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.TP.0000092307.98347.CB","article-title":"Familial Amyloidotic polyneuropathy world transplant registry. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial Amyloidotic polyneuropathy world transplant registry","volume":"77","author":"Herlenius","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100960_bb0105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/13506129.2023.2177986","article-title":"Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis","volume":"30","author":"Socie","year":"2023","journal-title":"Amyloid"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X25000606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X25000606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:55:04Z","timestamp":1763751304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X25000606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0955470X25000606"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2025.100960","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of disease-modifying drugs in patients with transthyretin amyloidosis after liver transplantation: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2025.100960","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100960"}}